Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10948823 | 0.79 | ALDH1A1 (0.52) | ALDH1A1ALOX15MAPTMEN1KMT2A | |
| SCHEMBL13943720 | 0.74 | MAPT (0.51) | ALDH1A1ALOX15MAPTMEN1KMT2A | |
| SCHEMBL2233882 | 0.71 | PADI4 (0.53) | ALDH1A1ALOX15MAPTMEN1KMT2A | |
| SCHEMBL2294425 | 0.70 | LIMK1 (0.53) | ALDH1A1ALOX15MAPTMEN1KMT2A | |
| SCHEMBL14139042 | 0.68 | KDM4E (0.44) | ALDH1A1ALOX15MAPTMEN1KMT2A | |
| SCHEMBL6503590 | 0.68 | GPR3 (0.55) | ALDH1A1ALOX15MAPTMEN1KMT2A | |
| SCHEMBL2469312 | 0.67 | LMNA (0.60) | ALDH1A1ALOX15MAPTMEN1KMT2A | |
| SCHEMBL10996327 | 0.66 | ALDH1A1 (0.38) | ALDH1A1ALOX15MAPTMEN1KMT2A | |
| SCHEMBL28479943 | 0.65 | MAPT (0.52) | ALDH1A1ALOX15MAPTMEN1KMT2A | |
| SCHEMBL28383390 | 0.65 | KDM4E (0.52) | ALDH1A1ALOX15MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2341904-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | Fibrogen, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010024908-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | PMP22, MAG, NEFM | ALDH1A1 2881/4885ALOX15 922/4885MAPT 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.